Union Therapeutics ready for phase III: "We're in a really good place"

However, the CFO will not disclose whether Union is looking for a partner or raising capital for an upcoming phase III study..
Union Therapeutics CFO Morten Boesen is not fully open about the company's exact plans for 2024.. | Photo: Morten Boesen, finansdirektør i Union Therapeutics
Union Therapeutics CFO Morten Boesen is not fully open about the company's exact plans for 2024.. | Photo: Morten Boesen, finansdirektør i Union Therapeutics

In 2024, Union Therapeutics is facing some crucial choices about the company’s lead candidate, PDE4 inhibitor orismilast, says the company’s CFO, Morten Boesen.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Foto: Mike Blake/Reuters/Ritzau Scanpix

    Gilead Sciences CMO to leave early 2025

    For subscribers

    Further reading